Search - tctmd.com

Displaying 1 - 20 of 27

Sort: Relevancy | Date

News Daily News

BMJ Investigation Revives Questions About PLATO, Ticagrelor

Todd Neale

December 20, 2024

News Daily News

Routine Use of GRACE Score Doesn’t Improve ACS Management: AGRIS

Todd Neale

December 16, 2020

News Conference News TCT 2019

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

Caitlin E. Cox

September 26, 2019

News TCT 2019

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

Shelley Wood

September 26, 2019

https://www.tctmd.com/news/ideal-lm-probes-short-dapt-and-bioabsorbable-polymer-stent-left-main-disease

News Conference News TCT 2019

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

Michael O'Riordan

September 26, 2019

News Conference News TCT 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Yael L. Maxwell

September 26, 2019

News Conference News ACC 2018

TREAT: No Major Bleeds With Ticagrelor in ACS Patients After Fibrinolysis

Shelley Wood

March 11, 2018

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

News Daily News

Former FDA Staffer Says Missing Data Across Antithrombotic Trials Cast Doubt on Drug Effects

Shelley Wood

January 18, 2016

News Daily News

FDA 的前职员表示，各抗血栓试验的缺失数据使得药物作用蒙上疑云

Shelley Wood

January 18, 2016

News Daily News

Antiguo Miembro de la FDA Dice que los Datos que Faltan sobre Ensayos Antitrombóticos arrojan una Sombra sobre los Efectos del Fármaco

Shelley Wood

January 18, 2016

News Conference News ACC 2015

Long-Term DAPT with Ticagrelor Reduces Ischemic Risk, Ups Bleeding in MI Patients

Todd Neale

March 14, 2015

News Conference News AHA 2014

Ezetimibe Proves Clinical Benefit on Top of Statin Therapy

November 16, 2014

News Conference News AHA 2014

DAPT Study Shows Benefit of Long-Term Treatment After DES Implantation

Yael L. Maxwell

November 16, 2014

Presentation TCT 2014

Does Cilostazol Have a Role as an Antiplatelet Agent in the Contemporary DES Era (and in Triple Therapy Decisions)?

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Frederick Feit

September 14, 2014

Presentation TCT 2014

Integrating a WOEST Aspirin Deletion Strategy Into Clinical Practice: When Is it Appropriate?

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Freek W.A. Verheugt

September 14, 2014

Presentation TCT 2014

Featured Lecture: First Presentation of the PLATO Primary PCI Subgroup

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Philippe Gabriel Steg

September 14, 2014

Presentation TCT 2014

The Case for Selective Use of Prasugrel and Ticagrelor in PCI Patients with Stable CAD

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Matthew J. Price

September 14, 2014

Presentation TCT 2014

Featured Lecture: Aspirin, the Most Understood and Misunderstood Antiplatelet Agent

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Anthony A. Bavry

September 14, 2014

Presentation TCT 2013

Cangrelor Will Be the Answer for Most in the Acute Setting!

Presenter: Robert Harrington

October 31, 2013

Advertisement

BMJ Investigation Revives Questions About PLATO, Ticagrelor

Routine Use of GRACE Score Doesn’t Improve ACS Management: AGRIS

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

TREAT: No Major Bleeds With Ticagrelor in ACS Patients After Fibrinolysis

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Former FDA Staffer Says Missing Data Across Antithrombotic Trials Cast Doubt on Drug Effects

FDA 的前职员表示，各抗血栓试验的缺失数据使得药物作用蒙上疑云

Antiguo Miembro de la FDA Dice que los Datos que Faltan sobre Ensayos Antitrombóticos arrojan una Sombra sobre los Efectos del Fármaco

Long-Term DAPT with Ticagrelor Reduces Ischemic Risk, Ups Bleeding in MI Patients

Ezetimibe Proves Clinical Benefit on Top of Statin Therapy

DAPT Study Shows Benefit of Long-Term Treatment After DES Implantation

Does Cilostazol Have a Role as an Antiplatelet Agent in the Contemporary DES Era (and in Triple Therapy Decisions)?

Integrating a WOEST Aspirin Deletion Strategy Into Clinical Practice: When Is it Appropriate?

Featured Lecture: First Presentation of the PLATO Primary PCI Subgroup

The Case for Selective Use of Prasugrel and Ticagrelor in PCI Patients with Stable CAD

Featured Lecture: Aspirin, the Most Understood and Misunderstood Antiplatelet Agent

Cangrelor Will Be the Answer for Most in the Acute Setting!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content